WO2021030153A3 - Engineered t cell receptors and uses thereof - Google Patents
Engineered t cell receptors and uses thereof Download PDFInfo
- Publication number
- WO2021030153A3 WO2021030153A3 PCT/US2020/045250 US2020045250W WO2021030153A3 WO 2021030153 A3 WO2021030153 A3 WO 2021030153A3 US 2020045250 W US2020045250 W US 2020045250W WO 2021030153 A3 WO2021030153 A3 WO 2021030153A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- engineered
- cell receptors
- tcr
- domain
- intracellular
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70514—CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
Abstract
The invention relates to fusion proteins comprising a transmembrane domain and an intracellular domain capable of providing a stimulatory signal, and engineered T cell receptors comprising same. The disclosure provides, in part, engineered T cell receptors (TCR) comprising one or more signaling domain(s) fused to the intracellular portion of at least one TCR subunit.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962885023P | 2019-08-09 | 2019-08-09 | |
US62/885,023 | 2019-08-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2021030153A2 WO2021030153A2 (en) | 2021-02-18 |
WO2021030153A3 true WO2021030153A3 (en) | 2021-03-25 |
Family
ID=74571215
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2020/045250 WO2021030153A2 (en) | 2019-08-09 | 2020-08-06 | Engineered t cell receptors and uses thereof |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2021030153A2 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2020401315B2 (en) | 2019-12-11 | 2023-11-09 | A2 Biotherapeutics, Inc. | LILRB1-based chimeric antigen receptor |
US20230330227A1 (en) | 2020-08-13 | 2023-10-19 | A2 Biotherapeutics, Inc. | Gene fusions for control of genetically modified cells |
MX2023002017A (en) | 2020-08-20 | 2023-04-28 | A2 Biotherapeutics Inc | Compositions and methods for treating ceacam positive cancers. |
CA3188862A1 (en) | 2020-08-20 | 2022-02-24 | Carl Alexander Kamb | Compositions and methods for treating mesothelin positive cancers |
WO2022040444A1 (en) | 2020-08-20 | 2022-02-24 | A2 Biotherapeutics, Inc. | Compositions and methods for treating egfr positive cancers |
IL304857A (en) | 2021-02-16 | 2023-10-01 | A2 Biotherapeutics Inc | Compositions and methods for treating her2 positive cancers |
EP4323387A2 (en) * | 2021-04-13 | 2024-02-21 | Wugen, Inc. | Improved chimeric antigen receptors and uses thereof |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010039899A2 (en) * | 2008-09-30 | 2010-04-08 | University Of Southern California | Method for monitoring intracellular tyrosine phosphatase activity |
US20130266551A1 (en) * | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
US20160311901A1 (en) * | 2013-07-29 | 2016-10-27 | Bluebird Bio, Inc. | Multipartite signaling proteins and uses thereof |
WO2017096327A2 (en) * | 2015-12-03 | 2017-06-08 | Juno Therapeutics, Inc. | Compositions and methods for reducing immune responses against cell therapies |
US20180010095A1 (en) * | 2016-09-23 | 2018-01-11 | Adaptimmune Limited | T Cells with Increased Immunosuppression Resistance |
WO2018067993A1 (en) * | 2016-10-07 | 2018-04-12 | TCR2 Therapeutics Inc. | Compositions and methods for t-cell receptors reprogramming using fusion proteins |
WO2018193231A1 (en) * | 2017-04-18 | 2018-10-25 | Autolus Limited | Cell |
US20190022216A1 (en) * | 2015-10-23 | 2019-01-24 | Eureka Therapeutics, Inc. | Antibody/t-cell receptor chimeric constructs and uses thereof |
WO2019067677A1 (en) * | 2017-09-29 | 2019-04-04 | Cell Design Labs, Inc. | Methods of making bispecific anti-cd307e and anti-bcma chimeric antigen receptors and uses of the same |
US20190240304A1 (en) * | 2016-10-20 | 2019-08-08 | Celgene Corporation | Cereblon-based heterodimerizable chimeric antigen receptors |
-
2020
- 2020-08-06 WO PCT/US2020/045250 patent/WO2021030153A2/en active Application Filing
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130266551A1 (en) * | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
WO2010039899A2 (en) * | 2008-09-30 | 2010-04-08 | University Of Southern California | Method for monitoring intracellular tyrosine phosphatase activity |
US20160311901A1 (en) * | 2013-07-29 | 2016-10-27 | Bluebird Bio, Inc. | Multipartite signaling proteins and uses thereof |
US20190022216A1 (en) * | 2015-10-23 | 2019-01-24 | Eureka Therapeutics, Inc. | Antibody/t-cell receptor chimeric constructs and uses thereof |
WO2017096327A2 (en) * | 2015-12-03 | 2017-06-08 | Juno Therapeutics, Inc. | Compositions and methods for reducing immune responses against cell therapies |
US20180010095A1 (en) * | 2016-09-23 | 2018-01-11 | Adaptimmune Limited | T Cells with Increased Immunosuppression Resistance |
WO2018067993A1 (en) * | 2016-10-07 | 2018-04-12 | TCR2 Therapeutics Inc. | Compositions and methods for t-cell receptors reprogramming using fusion proteins |
US20190240304A1 (en) * | 2016-10-20 | 2019-08-08 | Celgene Corporation | Cereblon-based heterodimerizable chimeric antigen receptors |
WO2018193231A1 (en) * | 2017-04-18 | 2018-10-25 | Autolus Limited | Cell |
WO2019067677A1 (en) * | 2017-09-29 | 2019-04-04 | Cell Design Labs, Inc. | Methods of making bispecific anti-cd307e and anti-bcma chimeric antigen receptors and uses of the same |
Non-Patent Citations (1)
Title |
---|
COURTNEY ADAM H., LO WAN-LIN, WEISS ARTHUR: "TCR SIGNALING: MECHANISMS OF INITIATION AND PROPAGATION", TRENDS IN BIOCHEMICAL SCIENCES, vol. 43, no. 2, February 2018 (2018-02-01), pages 108 - 123, XP055805438, DOI: 10.1016/j.tibs.2017.11.008 * |
Also Published As
Publication number | Publication date |
---|---|
WO2021030153A2 (en) | 2021-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021030153A3 (en) | Engineered t cell receptors and uses thereof | |
AU2018351050A8 (en) | Compositions and methods for selective protein degradation | |
WO2017123650A3 (en) | Multivalent and multispecific 41bb-binding fusion proteins | |
WO2009091826A3 (en) | Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car) | |
MX2020013977A (en) | Chimeric transmembrane proteins and uses thereof. | |
SA517380842B1 (en) | Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use | |
WO2006000830A3 (en) | Cells expressing a modified t cell receptor | |
WO2017015623A3 (en) | Multivalent and multispecific gitr-binding fusion proteins | |
EP4241848A3 (en) | Tgf-beta receptor type ii fusion proteins and uses thereof | |
PT1421115E (en) | T SOLUVEL CELL RECEIVER | |
MXPA06010500A (en) | Anterior cervical plating system. | |
MX2018000278A (en) | Immune checkpoint chimeric antigen receptors therapy. | |
WO2000031258A3 (en) | Human orphan g protein-coupled receptors | |
AR115024A1 (en) | INTERLEUKIN-2 FUSION PROTEINS / INTERLEUKIN-2 RECEPTOR a AND METHODS OF USE | |
WO2015126480A3 (en) | Self-assembling underwater adhesives | |
WO2012142515A3 (en) | Fc fusion proteins comprising novel linkers or arrangements | |
MX366854B (en) | AGLYCOSYLATED Fc-CONTAINING POLYPEPTIDES. | |
EP3749683A4 (en) | Fgf21 variant, fusion protein and application thereof | |
EP3878461A4 (en) | TGF-ß RECEPTOR FUSION PROTEIN PHARMACEUTICAL COMPOSITION AND USE THEREOF | |
WO2018027039A8 (en) | Compositions and methods for modulating lair signal transduction | |
WO2019099921A3 (en) | Vegfr-fc fusion protein formulations | |
SG11202000115SA (en) | Novel therapeutic enzyme fusion protein and use thereof | |
EP3858866A4 (en) | Glp1-fc fusion protein and conjugate thereof | |
EP3836959A4 (en) | Anti-angiogenesis fusion protein and uses thereof | |
WO2020030979A8 (en) | New car constructs comprising tnfr2 domains |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20853221 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20853221 Country of ref document: EP Kind code of ref document: A2 |